|
Pralidoxime Chloride for Injection
» Pralidoxime Chloride for Injection contains not less than 90.0 percent and not more than 110.0 percent of the labeled amount of pralidoxime chloride (C7H9ClN2O).
Packaging and storage
Preserve in Containers for Sterile Solids as described under Injections
Identification
B:
A solution (1 in 10) meets the requirements of the tests for Chloride
C:
The retention time of the major peak in the chromatogram of the Assay preparation corresponds to that in the chromatogram of the Standard preparation, as obtained in the Assay.
Completeness of solution
Constituted solution
At the time of use, it meets the requirements for Constituted Solutions under Injections
Bacterial endotoxins
pH
Other requirements
It meets the requirements for Loss on drying and Heavy metals under Pralidoxime Chloride. It also meets the requirements for Sterility Tests
Assay
Dilute phosphoric acid solution, Tetraethylammonium chloride solution, Mobile phase, Standard preparation, System suitability preparation, and Chromatographic system
Proceed as directed in the Assay under Pralidoxime Chloride.
Assay preparation
Select an accurately counted number of containers of Pralidoxime Chloride for Injection, the combined contents of which are equivalent to about 10 g of pralidoxime chloride. Dissolve the contents of each container in water, and combine all of the solutions in a 1000-mL volumetric flask. Rinse each container with water, and add the rinsings to the volumetric flask. Dilute with water to volume, and mix. Transfer 25.0 mL of the resulting solution to a 200-mL volumetric flask, dilute with water to volume, and mix. Transfer 2.0 mL of this solution to a 100-mL volumetric flask, dilute with Mobile phase to volume, and mix.
Procedure
Proceed as directed for Procedure in the Assay under Pralidoxime Chloride. Calculate the quantity, in mg, of pralidoxime chloride (C7H9ClN2O) in each container of Pralidoxime Chloride for Injection taken by the formula:
400(C / N)(rU / rS)
in which N is the number of containers selected for the Assay preparation, and the other terms are as defined therein.
Auxiliary Information
Please check for your question in the FAQs before contacting USP.
USP35NF30 Page 4383
Pharmacopeial Forum: Volume No. 34(5) Page 1180
|